Northern Trust Corp Has $15.04 Million Stock Position in AtriCure, Inc. $ATRC

Key Points

• Northern Trust Corp reduced its stake in AtriCure, Inc. by 3.6%, holding 466,201 shares valued at approximately $15.04 million as of the end of the first quarter.
• AtriCure reported a 17.1% increase in quarterly revenue year-over-year, totaling $136.14 million, with an EPS of ($0.02), exceeding analysts' expectations.
• Analysts have a consensus rating of "Buy" for AtriCure, with nine analysts providing a price target range, including a rise from $44.00 to $45.00 by Needham & Company.

Northern Trust Corp lessened its stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 3.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 466,201 shares of the medical device company's stock after selling 17,406 shares during the quarter. Northern Trust Corp owned about 0.94% of AtriCure worth $15,040,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its position in shares of AtriCure by 24.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 700,212 shares of the medical device company's stock valued at $21,398,000 after buying an additional 136,015 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in AtriCure by 232.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,871 shares of the medical device company's stock valued at $88,000 after acquiring an additional 2,008 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in AtriCure by 8.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 43,596 shares of the medical device company's stock valued at $1,333,000 after acquiring an additional 3,267 shares during the last quarter. Algert Global LLC raised its position in AtriCure by 10.1% during the fourth quarter. Algert Global LLC now owns 96,199 shares of the medical device company's stock valued at $2,940,000 after purchasing an additional 8,787 shares in the last quarter. Finally, Ameriprise Financial Inc. bought a new stake in AtriCure during the fourth quarter worth $295,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

AtriCure Stock Performance

Shares of ATRC stock opened at $34.77 on Thursday. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of -45.16 and a beta of 1.62. The company has a current ratio of 3.94, a quick ratio of 2.83 and a debt-to-equity ratio of 0.16. The business's 50-day moving average price is $33.83 and its 200-day moving average price is $33.69. AtriCure, Inc. has a 12 month low of $25.50 and a 12 month high of $43.11.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.13. AtriCure had a negative net margin of 7.27% and a negative return on equity of 4.20%. The business had revenue of $136.14 million during the quarter, compared to analyst estimates of $130.17 million. During the same quarter last year, the business earned ($0.17) EPS. The firm's quarterly revenue was up 17.1% on a year-over-year basis. AtriCure has set its FY 2025 guidance at -0.390--0.340 EPS. Equities research analysts forecast that AtriCure, Inc. will post -0.6 EPS for the current year.

Insiders Place Their Bets

In related news, Director Sven Wehrwein sold 5,000 shares of AtriCure stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $37.00, for a total value of $185,000.00. Following the transaction, the director directly owned 34,374 shares of the company's stock, valued at $1,271,838. The trade was a 12.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Regina E. Groves sold 2,452 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $36.82, for a total transaction of $90,282.64. Following the completion of the transaction, the director owned 33,715 shares in the company, valued at $1,241,386.30. This trade represents a 6.78% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,952 shares of company stock valued at $546,733. 3.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

ATRC has been the subject of a number of research analyst reports. Needham & Company LLC boosted their price target on AtriCure from $44.00 to $45.00 and gave the stock a "buy" rating in a report on Wednesday, July 30th. Wall Street Zen raised AtriCure from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, BTIG Research set a $54.00 price target on shares of AtriCure in a research note on Wednesday, July 30th. Nine research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $50.89.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.